Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total value of $153,520.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.81% during trading on Wednesday, reaching $152.68. 326,163 shares of the company’s stock were exchanged. The company has a market capitalization of $9.17 billion, a PE ratio of 23.52 and a beta of 1.13. The company has a 50 day moving average price of $149.76 and a 200-day moving average price of $149.92. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/13/jazz-pharmaceuticals-plc-jazz-ceo-bruce-c-cozadd-sells-1000-shares.html.

A number of research analysts have weighed in on the company. Cowen and Company reissued an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $177.00 target price (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $177.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $192.00 target price (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Finally, BMO Capital Markets increased their target price on Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $180.96.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its stake in Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after acquiring an additional 849,348 shares during the period. Vanguard Group Inc. increased its stake in Jazz Pharmaceuticals PLC by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after acquiring an additional 153,908 shares during the period. BlackRock Inc. increased its stake in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after acquiring an additional 3,116,652 shares during the period. Janus Capital Management LLC increased its stake in Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after acquiring an additional 468,940 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Jazz Pharmaceuticals PLC by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares during the period. 88.24% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.